×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CYDY – cytodyn inc (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CYDY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/20
08:30 am
cydy
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
Medium
Report
CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference
1/27
04:47 pm
cydy
Former West Coast biotech CEO imprisoned for pocketing millions [Yahoo! Finance]
Low
Report
Former West Coast biotech CEO imprisoned for pocketing millions [Yahoo! Finance]
1/27
08:30 am
cydy
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
Low
Report
CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer
1/26
02:47 pm
cydy
Biotech exec gets prison for securities fraud [Investment Executive - News]
Low
Report
Biotech exec gets prison for securities fraud [Investment Executive - News]
12/16
09:23 am
cydy
December 2025 Letter to Shareholders [Yahoo! Finance]
Medium
Report
December 2025 Letter to Shareholders [Yahoo! Finance]
12/16
08:30 am
cydy
December 2025 Letter to Shareholders
Medium
Report
December 2025 Letter to Shareholders
12/8
08:30 am
cydy
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
Low
Report
CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium
12/1
08:41 am
cydy
CytoDyn Announces Resolution of Class Action Lawsuit [Yahoo! Finance]
Low
Report
CytoDyn Announces Resolution of Class Action Lawsuit [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/9
08:31 am
cydy
Form 10-Q CytoDyn Inc. For: Nov 30
Low
Report
Form 10-Q CytoDyn Inc. For: Nov 30
12/1
08:40 am
cydy
Form 8-K CytoDyn Inc. For: Nov 23
Low
Report
Form 8-K CytoDyn Inc. For: Nov 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/30
Three Additional Patients with Severe COVID-19 Treated with Leronlimab in New York Medical Center Bringing the Total to 10 Patients
90.5%
12/19 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock, up previously from $1.00. 50.5%
3/27 CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA 46.1%
12/17 CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV 38.6%
1/31 CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition 20.2%
4/3 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock, up previously from $1.50. 18.7%
4/27 CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients 17.3%
4/24 CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine 15.6%
4/1 CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks 15.2%
5/9 Form 8-K CytoDyn Inc. For: May 08 15.1%
12/19 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $1.50 price target on the stock, up previously from $1.00. 50.5%
3/27 CytoDyn Files FDA-Suggested Modifications to IND and Protocol for Phase 2 Clinical Trial for COVID-19 Patients with Mild to Moderate Indications and a Second Randomized Protocol for All COVID-19 Patients in Severe Condition Will be Filed Next Week per FDA 46.1%
12/17 CytoDyn Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV 38.6%
1/31 CytoDyn Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition 20.2%
4/3 CytoDyn Inc (OTCMKTS: CYDY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock, up previously from $1.50. 18.7%
4/27 CytoDyn Submits Completed Biologics License Application (BLA) to the FDA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients 17.3%
4/24 CytoDyn to Hold Conference Call to Provide Updates on Completion of BLA Filing for HIV, Timeline for Potential Approval of Treatment for COVID-19 Patients, and Two Publications, Including The New England Journal of Medicine 15.6%
4/1 CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks 15.2%
5/9 Form 8-K CytoDyn Inc. For: May 08 15.1%
TOP News Decliners
4/2
Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients
-23.5%
2/6 CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers -11.5%
4/30 Form S-3/A CytoDyn Inc. -8.7%
5/15 CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA -8.3%
5/22 Form 8-K CytoDyn Inc. For: May 22 -7.5%
5/14 CytoDyn Strengthens Management Team with Key Additions in Business Development and Quality Regulatory Compliance as it Advances Commercialization Plan for Leronlimab -7.4%
3/31 Cytodyn’s Leronlimab Could Be an Answer to COVID-19 [Yahoo! Finance News] -7.0%
4/28 Form 8-K CytoDyn Inc. For: Apr 24 -7.0%
1/2 CytoDyn: Buy, Sell, Or Hold Following PRO 140 Commercial Agreement [Seeking Alpha] -6.7%
4/27 Form 8-K CytoDyn Inc. For: Apr 23 -6.4%
2/6 CytoDyn Files a Phase 2 Basket Trial with Leronlimab (PRO 140) for Treatment of All Solid Tumor Cancers -11.5%
4/30 Form S-3/A CytoDyn Inc. -8.7%
5/15 CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA -8.3%
5/22 Form 8-K CytoDyn Inc. For: May 22 -7.5%
5/14 CytoDyn Strengthens Management Team with Key Additions in Business Development and Quality Regulatory Compliance as it Advances Commercialization Plan for Leronlimab -7.4%
3/31 Cytodyn’s Leronlimab Could Be an Answer to COVID-19 [Yahoo! Finance News] -7.0%
4/28 Form 8-K CytoDyn Inc. For: Apr 24 -7.0%
1/2 CytoDyn: Buy, Sell, Or Hold Following PRO 140 Commercial Agreement [Seeking Alpha] -6.7%
4/27 Form 8-K CytoDyn Inc. For: Apr 23 -6.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: